Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 116
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | ||
| NCT01070797 | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) | ||
| NCT00058773 | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease | ||
| NCT00539695 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD | ||
| NCT00609219 | T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC | ||
| NCT00048412 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | ||
| NCT00078520 | Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells | ||
| NCT00056966 | Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases | ||
| NCT07197749 | Vitamin C With Steroids for Gastrointestinal GVHD | ||
| NCT02291848 | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma | ||
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | ||
| NCT00902044 | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | ||
| NCT01702961 | Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | ||
| NCT00515957 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) | ||
| NCT04345601 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | ||
| NCT02494167 | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | ||
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML | ||
| NCT00082225 | LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL) | ||
| NCT00058591 | Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) | ||
| NCT00040469 | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | ||
| NCT00880789 | Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus | ||
| NCT01333046 | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | ||
| NCT01604031 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide | ||
| NCT04401410 | Anti-SARS Cov-2 T Cell Infusions for COVID 19 | ||
| NCT03762291 | Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine | ||
| NCT03478215 | Mesenchymal Stromal Cells in Living Donor Kidney Transplantation | ||
| NCT00881920 | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL | ||
| NCT00516087 | LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) | ||
| NCT03192462 | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer | ||
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM | ||
| NCT01713439 | Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL | ||
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | ||
| NCT02050347 | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) | ||
| NCT02379520 | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA | ||
| NCT02439788 | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA | ||
| NCT00078533 | Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant | ||
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme | ||
| NCT01953900 | iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma | ||
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | ||
| NCT00578903 | Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia | ||
| NCT01247688 | Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies | ||
| NCT03294954 | GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma | ||
| NCT02442297 | T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors | ||
| NCT06251544 | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | ||
| NCT02276820 | Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) | ||
| NCT01822652 | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | ||
| NCT01945619 | Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH) | ||
| NCT00579137 | Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders | ||
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | ||
| NCT00058617 | Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL |
